| View Archive: 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 June 26, 2009 European CHMP Adopts Positive Opinion for Aztreonam Lysine
June 18, 2009 Gilead Sciences to Present at the Piper Jaffray 4th Annual Europe Conference on Wednesday, June 24
June 2, 2009 Gilead Sciences to Present at Two Upcoming Investor Conferences
May 28, 2009 Gilead Sciences' Marketing Authorisation Application for Regadenoson Validated by European Medicines Agency
May 22, 2009 Gilead Sciences Announces Changes to Cardiovascular R
&
D Organization Leadership
May 18, 2009 New Data for Gilead Sciences' Ambrisentan Show Clinical Improvements in a Diverse Pulmonary Hypertension (PH) Population
May 15, 2009 Gilead Sciences to Present at the Deutsche Bank 34th Annual Healthcare Conference on Tuesday, May 19
May 14, 2009 Gilead Sciences Files Second Patent Infringement Lawsuit Against Teva Pharmaceuticals
May 12, 2009 Gilead Palo Alto, Inc. Announces Tender Offer for Convertible Notes May 8, 2009 Gilead Sciences' Phase III Darusentan Data Show Significant Blood Pressure Reductions in Resistant Hypertension Patients
April 21, 2009 Gilead Sciences Announces Record First Quarter 2009 Financial Results April 17, 2009 Gilead Sciences Completes Acquisition of CV Therapeutics
April 17, 2009 Gilead Initiates Phase II Clinical Trial of Integrase-Based, Single-Tablet, Once-Daily Regimen for the Treatment of HIV
April 15, 2009 Gilead Sciences Successfully Completes Tender Offer for Shares of CV Therapeutics With Over 88 Percent of Shares Tendered April 14, 2009 Gilead Sciences to Release First Quarter 2009 Financial Results on Tuesday, April 21, 2009
April 13, 2009 Phase III Data for Gilead Sciences' Darusentan Accepted as Late-Breaker Presentation at ASH 2009
April 6, 2009 Gilead Sciences Announces Notification of ANDA Filing for Atripla(R) April 2, 2009 Phase III Study of Gilead's Darusentan for Resistant Hypertension Meets Primary Endpoints
March 31, 2009 Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting Period
March 24, 2009 Gilead Initiates Phase II Clinical Trial of Cicletanine for the Treatment of Pulmonary Arterial Hypertension
March 19, 2009 European CHMP Adopts Negative Opinion on Aztreonam Lysine
March 13, 2009 Department of Justice Declines to Intervene in False Claims Act Lawsuits Against Gilead Sciences
March 12, 2009 Gilead Sciences Agrees to Acquire CV Therapeutics for $20.00 Per Share
March 11, 2009 Gilead Sciences to Present at the Cowen and Company 29th Annual Healthcare Conference on Monday, March 16
March 6, 2009 Gilead Sciences to Present at the Barclays Capital Global Healthcare Conference on Tuesday, March 10
February 18, 2009 Gilead Receives Response From U.S. FDA on Company's Request for Formal Dispute Resolution for Aztreonam for Inhalation Solution
February 9, 2009 Gilead Announces Data Demonstrating Pharmacokinetic Boosting Activity of GS 9350 February 6, 2009 Gilead Sciences to Present at the 11th Annual BIO CEO Investor Conference on Tuesday, February 10
February 2, 2009 Gilead Announces Senior Management Promotion
January 29, 2009 Gilead Completes Acquisition of Building and Associated Land from EFI
January 27, 2009 Gilead Outlines R
&
D Priorities for 2009
January 27, 2009 Gilead Sciences Announces Record Fourth Quarter and Full Year 2008 Financial Results
January 16, 2009 Gilead Sciences to Release Fourth Quarter and Year End 2008 Financial Results on Tuesday, January 27, 2009
January 7, 2009 Gilead Sciences to Present at the 27th Annual JPMorgan Healthcare Conference on Monday, January 12 |